NCM
GYRE icon

Nantahala Capital Management’s Gyre Therapeutics GYRE Stock Holding History

Nantahala Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,520
Closed -$32.7K – 134
2023
Q3 		$32.7K Hold
4,520
– – ﹤0.01% 130
2023
Q2 		$23.8K Sell
4,520
-6,175
-58% -$22.1K ﹤0.01% 122
2023
Q1 		$33.2K Sell
10,695
-47,712
-82% -$181K ﹤0.01% 121
2022
Q4 		$231K Sell
58,407
-282,224
-83% -$1.15M 0.02% 108
2022
Q3 		$1.29M Sell
340,631
-26,823
-7% -$341K 0.08% 85
2022
Q2 		$4.91M Buy
367,454
+44,682
+14% +$297K 0.25% 62
2022
Q1 		$1.6M Sell
322,772
-45,449
-12% -$225K 0.07% 94
2021
Q4 		$2.52M Buy
368,221
+43,926
+14% +$751K 0.09% 97
2021
Q3 		$10M Sell
324,295
-13,220
-4% -$435K 0.32% 63
2021
Q2 		$11M Sell
337,515
-3,996
-1% -$137K 0.31% 67
2021
Q1 		$12.9M Buy
341,511
+92,800
+37% +$4.24M 0.38% 54
2020
Q4 		$11.8M Buy
248,711
+5,811
+2% +$252K 0.36% 59
2020
Q3 		$7.83M Hold
242,900
– – 0.24% 71
2020
Q2 		$10.7M Buy
242,900
+50,000
+26% +$2.35M 0.32% 59
2020
Q1 		$6.32M Buy
192,900
+50,000
+35% +$2.3M 0.24% 61
2019
Q4 		$7.3M Buy
142,900
+1,188
+0.8% +$49.8K 0.22% 57
2019
Q3 		$5.22M Buy
141,712
+2,666
+2% +$144K 0.19% 69
2019
Q2 		$7.69M Buy
139,046
+11,280
+9% +$705K 0.24% 58
2019
Q1 		$7.77M Buy
127,766
+13,734
+12% +$883K 0.24% 56
2018
Q4 		$6.75M Buy
+114,032
New +$8.41M 0.21% 69

Other funds holding GYRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $58.9B AUM 51.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Nantahala Capital Management's GYRE Position: Q4 2023 in Review

Nantahala Capital Management sold out of Gyre Therapeutics (GYRE) in Q4 2023, closing a stake of 4,520 shares — an estimated $32.7K sold.

Nantahala Capital Management first reported a position in GYRE in Q4 2018 and held it in 20 quarters. The position peaked at $12.9M in Q1 2021. 16 funds tracked by Wall St. Rank hold GYRE as of Q4 2023.

  • Nantahala Capital Management reported no remaining Gyre Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Nantahala Capital Management sold 4,520 Gyre Therapeutics shares in Q4 2023, an estimated $32.7K.
  • Nantahala Capital Management first reported a position in Gyre Therapeutics in Q4 2018 and held it in 20 quarters.
  • Nantahala Capital Management's Gyre Therapeutics position peaked at $12.9M in Q1 2021.
  • 16 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2023.

Based on Nantahala Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.